The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease

Current Pharmaceutical Design

Volumn 11, Issue 8, 2005, Pages 1047-1053

  Kanauchi, Osamu ^a   Matsumoto, Yoshiaki ^b   Matsumura, Masae ^b   Fukuoka, Masamichi ^b   Bamba, Tadao ^c  

^a KIRIN BREWERY CO LTD   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Antibiotics; Crohn's disease; Germinated barley foodstuff; Intestinal microflora; Prebiotics; Probiotics; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; BUTYRIC ACID; CIPROFLOXACIN; INTERLEUKIN 6; ISPAGULA; MESALAZINE; METRONIDAZOLE; OLIGOSACCHARIDE; PREBIOTIC AGENT; PROBIOTIC AGENT;

ANAEROBIC BACTERIUM; ANTIINFLAMMATORY ACTIVITY; BACTERIAL METABOLISM; BACTEROIDES; BARLEY; BIFIDOBACTERIUM; CLOSTRIDIUM BUTYRICUM; CLOSTRIDIUM DIFFICILE; COMMENSALISM; CROHN DISEASE; CYTOKINE PRODUCTION; DIETARY FIBER; DRUG EFFICACY; DRUG USE; ENTERITIS; ENTEROSTOMY; ESCHERICHIA COLI; EUBACTERIUM; EUBACTERIUM LIMOSUM; FERMENTATION; GERMINATION; HUMAN; INTESTINE CELL; INTESTINE EPITHELIUM; INTESTINE FLORA; LACTOBACILLUS; MILK; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; REVIEW; STREPTOCOCCUS THERMOPHILUS; TISSUE GROWTH; ULCERATIVE COLITIS;

ANIMALS; BACTERIA, ANAEROBIC; COLON; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA;

EID: 14744305964     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053381675     Document Type: Review

References (62)

1. Podolsky DK, Fiocchi C. In: Inflammatory Bowel Disease, 5th Ed. Kirsner JB, Saunders WB. Company: Philadelphia 2000; p. 191-207.
2. Hanauer SB, Kane S. The pharmacology of anti-inflammatory drugs in inflammatory bowel disease. In: Kirsner JB, ed. Inflammatory bowel disease. 5th ed. Philadelphia: W.B. Saunders Company 2000; 510-528.
3. Shanahan F. Immunology. Therapeutic manipulation of gut flora. Science 2000; 289: 1311-1312.
4. Gionchetti P, Rizzello F, Venturi A, Campieri M. Probiotics in infective diarrhea and inflammatory bowel diseases. J Gastroenterol and Hepatol 2000; 15: 489-493.
5. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am 1995; 24: 475-507.
6. Turunen UM, Farkkila MA, Hakala K, Seppala K, Sivonen A, Ogren M, et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology. 1998; 115: 1072-1078.
7. Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, Owen MJ. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol. 1997; 150: 91-97.
8. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjarnason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut. 1996; 38: 365-375.
9. Cong Y, Konrad A, Iqbal N, Elson CO. Probiotics and immune regulation of inflammatory bowel diseases. Curr Drug Targets Inflamm Allergy 2003; 2: 145-154.
10. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-519.
11. Kanauchi O, Mitsuyama K, Araki Y, Andoh A. Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr Pharm Des 2003; 9: 333-346.
12. Gibson GR. Dietary modulation of the human gut microflora using the prebiotics oligofructose and inulin. J Nutr 1999; 129 (7 Suppl): 1438S-1441S.
13. Morishita Y. Structure and function of microflora (In Japanese), Asakura-shoten: Tokyo, 1990.
14. Tuomola EM, Ouwehand AC, Salminen SJ. The effect of probiotic bacteria on the adhesion of pathogens to human intestinal mucus. FEMS Immunol Med Microbiol 1999; 26: 137-142.
15. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116: 1107-1114.
16. Matsumoto S, Okabe Y, Setoyama H, Takayama K, Olusuka J, Funahashi H, et al. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 1998; 43: 71-78.
17. Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis 2000; 6: 107-115.
18. Hans W, Scholmerich J, Gross V, Falk W. The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced coylitis in mice. Eur J Gastroenterol Hepatol 2000; 12: 267-273.
19. Gionchetti P, Amadini C, Rizzello F, Venturi A, Campieri M. Treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther 2002; 16 Suppl 4: 13-9.
20. Videla S, Vilaseca J, Guarner F, Salas A, Treserra F, Crespo E, et al. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 1994; 35: 1090-1097.
21. Kanauchi O, Mitsuyama K, Araki Y, Andoh A. Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr Pharm Des 2003; 9: 333-346.
22. Linskens RK, Huijsdens XW, Savelkoul PH, Vandenbroucke-Grauls CM, Meuwissen SG. The bacteria flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol Suppl 2001: 234: 29-40.
23. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103-1108.
24. Dunne C. Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Inflamm Bowel Dis 2001; 7: 136-45.
25. Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 41-62.
26. Moore WEC, Moore LVH. Genus Eubacterium. In Bargey's Manual of Systemic Bacteriology. Holt JG (eds). Williams & Winkins, Baltimore 1986; 2: 1141-1161.
27. Bouhnik Y, Pochart P, Marteau P, Arlet G, Goderel I, Rambaud JC. Fecal recovery in humans of viable Bifidobacterium sp. ingested in fermented milk. Gastroenterology 1992; 102: 875-878.
28. Roberfroid MB. Prebiotics and probiotics: are they functional foods? Am J Clin Nutr 2000; 71: 1682S-1687S.
29. Collins MD, Gibson GR. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 1999; 69: 1052S-1057S.
30. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 1202-1209.
31. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-309.
32. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999, 354: 635-639.
33. Boudeau J, Glasser AL, Julien S, Colombel JF, Darfeuille-Michaud A. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 45-56.
34. Fukuda M, Kanauchi O, Araki Y, Andoh A, Mitsuyama K, Takagi K, et al. Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. Int J Mol Med 2002; 9: 65-70.
35. Araki Y, Fujiyama Y, Andoh A, Koyama S, Kanauchi O, Bamba T. The dietary combination of germinated barley foodstuff plus Clostridium butyricum Suppresses the dextran sulfate sodium-induced experimental colitis in rats. Scand J Gastroenterol 2000; 35: 1060-1067.
36. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125: 1401-12.
37. Mitsuyama K, Toyonaga A, Sata M. Intestinal microflora as a therapeutic target in inflammatory bowel disease. J Gastroenterol. 2002; 37(Suppl 14): 73-7.
38. Kanauchi O, Serizawa I, Araki Y, Suzuki A, Andoh A, Fujiyama Y. et al. Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol 2003; 38: 134-41.
39. Breuer RI, Buto SK, Christ ML, Bean J, Vernia P, Paoluzi P, et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Dig Dis Sci 1991; 36: 185-187.
40. Scheppach W, Sommer H, Kirchner T, Paganelli G-M, Bartram P, Christl S, et al. Effect of butryrate enemas on the colonic mucosa in distal ulcreative colitis. Gastroenterology 1992; 103: 51-56.
41. Steinhart AH, Brzezinski A, Baker JP. Treatment of refractory ulcrative proctosigmoiditis with butyrate enemas. Am J Gastroenterol 1994; 89: 179-182.
42. Teramoto F, Rokutan K, Kawakami Y, Fujimura Y, Uchida J, Oku K, et al. Effect of 4G-beta-D-galactosylsucrose (lactosucrose). on fecal microflora in patients with chronic inflammatory bowel disease. J Gastroenterol 1996; 31: 33-9.
43. Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol 1991; 26: 747-50
44. Fernandez BF, Hinojosa J, Sanchez LJL, Navarro E, Martinez SJF, Garcias PA, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber). as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999; 94: 427-433.
45. Kanauchi O, Agata K. Protein and dietary fiber-rich new foodstuff from brewer's spent grain increased excretion of feces and jejunum mucosal protein content in rats. Biosci Biotech Biochem 1997; 61: 29-33.
46. Kanauchi O, Agata K, Fushiki T. Mechanism for the increased defecation and jejunum mucosal protein content in rats by feeding germinated barley foodstuff. Biosci Biotech Biochem 1997; 61: 443-448.
47. Mitsuyama K, Saiki T, Kanauchi O, Iwanaga T, Tomiyasu N, Nishiyama T, el al. Treatment of ulcerative colitis with germinated barley foodstuff. a pilot study. Aliment Pharmacol Ther 1998; 12: 1225-1230.
48. Kanauchi O, Mitsuyama K, Andoh A, Fujiyama Y, Sata M, Bamba T, et al. Beneficial effects of prebiotics, germinated barley foodstuff, in the long term treatment of ulcerative colitis; a multi center open control study. Gastroenterol 2003; 124: A1749.
49. Kanauchi O, Suga T, Tochihara M, Hibi T, Naganuma M, Homma T, et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol 2002; 37(Suppl 14): 67-72.
50. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002; 20: 495-549.
51. Steinhart AH, Hiruki T, Brzezinski A, Baker JP. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 1996; 10: 729-36.
52. Kanauchi O, Iwanaga T, Mitsuyama K, Saiki T, Tsuruta O, Noguchi K, et al. Butyrate from bacterial fermentation of germinated barley foodstuff preserves intestinal barrier function in experimental colitis in the rat model. J Gastroenterol Hepatol. 1999; 14: 880-888.
53. Barcenilla A, Pryde SE, Martin JC, Duncan SH, Stewart CS, Henderson C, el al. Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl Environ Microbiol. 2000; 66: 1654-1661.
54. Ohkusa T, Okayasu I, Ogihara T, Morita K. Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003; 52: 79-83.
55. Kanauchi O, Fujiyama Y, Mitsuyama K, Araki Y, Ishii T, Nakamura T, et al. Increased growth of Bifidobacterium and Eubacterium by germinated barley foodstuff, accompanied by enhanced butyrate production in healthy volunteers. Int J Mol Med 1999 3: 175-179.
56. Kleessen B, Kroesen AJ, Buhr HJ, Blaut M. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol 2002; 37: 1034-1041.
57. Andoh A, Fujiyama Y, Hata K, Araki Y, Takaya H, Shimada M, et al. Counter-regulatory effect of sodium butyrate on tumor necrosis factor-alpha (TNF-alpha)-induced complement C3 and factor B biosynthesis in human intestinal epithelia cells. Clin Exp Immunol 1999; 118: 23-9.
58. Sitaraman SV, Merlin D, Wang L, Wong M, Gewirtz AT, Si-Tahar M, et al. Related Articles, Links Neutrophil-epithelial crosstalk at the intestinal lumenal surface mediated by reciprocal secretion of adenosine and IL-6. J Clin Invest 2001; 107: 861-869.
59. Nakamura M, Tamura G, Takahashi N. Distribution by solvent extraction. In: Agricultural chemistry experiment 1 3rd edn. Tokyo, Asakura Shoten 1978; 202-203 (In Japanese).
60. D'Haens G. Anti-TNF therapy for Crohn's disease. Curr Pharm Design 2003; 9(4): 289-94.
61. Famularo G, Mosca L, Minisola G, Trinchieri V, De Simone C. Probiotic lactobacilli: a new perspective for the treatment of inflammatory bowel disease. Curr Pharm Design 2003; 9(24): 1973-80.
62. Kanauchi O, Mitsuyama K, Araki Y, Andoh A. Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr Pharm Design 2003; 9(4): 333-46.